Medison Ventures was among the participants in a round that will fund clinical tests for Alpha Tau's radiation-based cancer treatment.

Existing backers AstraZeneca and Johnson & Johnson returned for a round that will advance PhaseBio's orphan disease drug pipeline, based on research from Duke University.

The cancer therapy developer has secured $120m in a convertible note offering featuring the University of California office of the chief investment officer.

Existing backers AstraZeneca and Johnson & Johnson returned for a round that will advance PhaseBio's orphan disease drug pipeline.

The Pfizer-backed cancer therapy developer has secured $120m in a convertible note offering led by Perceptive Advisors.

Vesalius has provided $4.7m to Forendo Pharma, whose existing shareholders also include Karolinska Development, Novartis, Novo and Merck Group.

Chiesi Ventures and Pfizer Ventures have helped gene therapy developer 4D Molecular Therapeutics complete its series B round.

Sanofi Ventures and the WuXi AppTec-backed 6 Dimensions Capital contributed to a series B round that took Fulcrum Therapeutics' total funding to $140m.

Berkeley Catalyst Fund has helped close a $90m series B round for 4D Molecular Therapeutics, which emerged out of UC Berkeley.